Eli Lilly and Company, a major pharmaceutical corporation based in Indiana, has set up a new Web site intended for health care professionals as well as consumers. The innovative diabetes home page presents itself as a wealthy source of information on diabetes management in general and the use of a practical new insulin delivery device in particular.
Recently, the company has developed a convenient pre-filled and disposable insulin delivery device for patients with diabetes. On the newly launched Web site, patients receive clear guidance with regard to the use of the Humulin N and Humalog Pens, which were introduced to the market in February 1999.
The pens are specifically designed to make it very convenient for people with diabetes to administer Humulin 70/30, Humulin N, and Humalog for an adequate control of the patients' blood sugar levels. The Humulin 70/30 solution contains 70 percent human insulin isophane suspension and 30 percent human insulin injection [rDNA origin]. Humulin N consists of NPH human insulin [rDNAorigin] isophane suspension, whereas the Humalog medicine constitutes an insulin lispro injection [rDNA origin].
Diabetes patients who are interested to learn more about this user-friendly advance in insulin delivery, can navigate easily through product information and demonstrations. It is also possible to request a free video and sign up for the Lilly Diabetes Today newsletter. Visitors to the Web site additionally are able to review information on both diabetes education and the history of the development of insulin.
The new site applies the Macromedia Flash tool, an innovation in multimedia technology, to illustrate the delivery device's functionality and to enhance the visitor's experience by increasing the degree of interaction. A user-driven, step-by-step demonstration of the insulin pen's features represents a truly innovative trend for the pharmaceutical industry.